

# Nicholas P Restifo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9206371/nicholas-p-restifo-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

300  
papers

60,657  
citations

118  
h-index

245  
g-index

319  
ext. papers

68,766  
ext. citations

14.8  
avg, IF

7.68  
L-index

#	Paper	IF	Citations
300	Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. <i>Current Opinion in Immunology</i> , <b>2021</b> , 74, 39-45	7.8	2
299	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	21
298	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. <i>Cytotherapy</i> , <b>2021</b> , 23, 704-714	4.8	0
297	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. <i>Immunity</i> , <b>2021</b> , 54, 116-131.e10	32.3	18
296	An engineered IL-2 partial agonist promotes CD8 T cell stemness. <i>Nature</i> , <b>2021</b> , 597, 544-548	50.4	14
295	Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. <i>Cancer Cell</i> , <b>2020</b> , 37, 818-833.e9	24.3	48
294	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models <b>2020</b> , 8,		15
293	Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1267-1276	12.9	33
292	Multimodal preclinical platform predicts clinical response of melanoma to immunotherapy. <i>Nature Medicine</i> , <b>2020</b> , 26, 781-791	50.5	29
291	Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 5688	4.9	4
290	Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy. <i>Cell</i> , <b>2020</b> , 183, 591-593	36.2	10
289	A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	1
288	Defining 'T cell exhaustion'. <i>Nature Reviews Immunology</i> , <b>2019</b> , 19, 665-674	36.5	387
287	Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. <i>Molecular Cell</i> , <b>2019</b> , 73, 1162-1173.e5	17.6	42
286	Mg regulation of kinase signaling and immune function. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 1828-1842	16.6	16
285	T cell stemness and dysfunction in tumors are triggered by a common mechanism. <i>Science</i> , <b>2019</b> , 363,	33.3	196
284	Host conditioning with IL-1 $\beta$ improves the antitumor function of adoptively transferred T cells. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 2619-2634	16.6	26

283	The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction. <i>Cell</i> , <b>2019</b> , 178, 1088-1101.e15	56.2	91
282	Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1805-1817	7.4	19
281	Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	2
280	An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	19
279	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1551-1565	15.9	69
278	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1109-1114	15.9	119
277	The transcription factor c-Myb regulates CD8 T cell stemness and antitumor immunity. <i>Nature Immunology</i> , <b>2019</b> , 20, 337-349	19.1	57
276	Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. <i>Journal of Immunotherapy</i> , <b>2019</b> , 42, 126-135	5	116
275	Developing neoantigen-targeted T cell-based treatments for solid tumors. <i>Nature Medicine</i> , <b>2019</b> , 25, 1488-1499	50.5	90
274	The Cish SH2 domain is essential for PLC- $\beta$ regulation in TCR stimulated CD8 T cells. <i>Scientific Reports</i> , <b>2018</b> , 8, 5336	4.9	11
273	Epigenetic control of CD8 T cell differentiation. <i>Nature Reviews Immunology</i> , <b>2018</b> , 18, 340-356	36.5	181
272	A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. <i>Scientific Reports</i> , <b>2018</b> , 8, 2743	4.9	49
271	Silencing stemness in T cell differentiation. <i>Science</i> , <b>2018</b> , 359, 163-164	33.3	13
270	Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. <i>Cell Reports</i> , <b>2018</b> , 22, 3175-3190	10.6	25
269	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	61
268	Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. <i>Cell</i> , <b>2018</b> , 175, 1780-1795.e19	56.2	236
267	Metabolic reprogramming of anti-tumor immunity. <i>Current Opinion in Immunology</i> , <b>2017</b> , 46, 14-22	7.8	63
266	Novel "Elements" of Immune Suppression within the Tumor Microenvironment. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 426-433	12.5	43

265	BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. <i>Nature Immunology</i> , <b>2017</b> , 18, 813-823	19.1	79
264	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2478-2490	12.9	71
263	ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 6267-6281	10.1	12
262	Identification of essential genes for cancer immunotherapy. <i>Nature</i> , <b>2017</b> , 548, 537-542	50.4	460
261	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. <i>Cell Metabolism</i> , <b>2017</b> , 26, 94-109	24.6	206
260	Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2267-2276	12.9	41
259	Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	94
258	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. <i>Cell</i> , <b>2016</b> , 166, 1117-1131.e14	56.2	151
257	Ionic immune suppression within the tumour microenvironment limits T cell effector function. <i>Nature</i> , <b>2016</b> , 537, 539-543	50.4	313
256	Arginine Arms T Cells to Thrive and Survive. <i>Cell Metabolism</i> , <b>2016</b> , 24, 647-648	24.6	6
255	Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. <i>Journal of Immunology</i> , <b>2016</b> , 197, 644-54	5.3	14
254	Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning <b>2016</b> , 4, 6		14
253	Acquired resistance to immunotherapy and future challenges. <i>Nature Reviews Cancer</i> , <b>2016</b> , 16, 121-6	31.3	260
252	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. <i>Cell Metabolism</i> , <b>2016</b> , 23, 63-76	24.6	210
251	Targeting Akt in cell transfer immunotherapy for cancer. <i>Oncotmunology</i> , <b>2016</b> , 5, e1014776	7.2	4
250	Prospects for gene-engineered T cell immunotherapy for solid cancers. <i>Nature Medicine</i> , <b>2016</b> , 22, 26-36	50.5	243
249	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 204-14	12.5	115
248	Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 318-34	15.9	152

247	The transcription factor BACH2 promotes tumor immunosuppression. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 599-604	15.9	39
246	Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. <i>Nature Communications</i> , <b>2016</b> , 7, 13895	17.4	32
245	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2389-97	2.2	220
244	BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. <i>Nature Immunology</i> , <b>2016</b> , 17, 851-860	19.1	136
243	Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. <i>Cellular and Molecular Immunology</i> , <b>2016</b> , 13, 502-13	15.4	70
242	Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. <i>Cell</i> , <b>2016</b> , 167, 304-306	6.2	4
241	A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1019-27	12.9	494
240	Adoptive cell transfer as personalized immunotherapy for human cancer. <i>Science</i> , <b>2015</b> , 348, 62-8	33.3	1420
239	The interplay of effector and regulatory T cells in cancer. <i>Current Opinion in Immunology</i> , <b>2015</b> , 33, 101-118	11.8	88
238	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. <i>Molecular Therapy</i> , <b>2015</b> , 23, 1380-1390	11.7	67
237	Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1543-50	2.2	356
236	Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. <i>Journal of Experimental Medicine</i> , <b>2015</b> , 212, 2095-113	16.6	85
235	Nutrient Competition: A New Axis of Tumor Immunosuppression. <i>Cell</i> , <b>2015</b> , 162, 1206-8	56.2	69
234	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. <i>Cellular and Molecular Immunology</i> , <b>2015</b> ,	15.4	7
233	Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. <i>Vaccine</i> , <b>2015</b> , 33, 914-23	4.1	25
232	Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 37-47	12.5	22
231	Inhibition of the T cell oxygen sensing machinery promotes anti-tumor efficacy <b>2015</b> , 3,		78
230	The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. <i>ELife</i> , <b>2015</b> , 4,	8.9	33

229	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>OncImmunology</i> , <b>2015</b> , 4, e998538	7.2	101
228	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2278-88	12.9	214
227	miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic $\beta$ cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 476-81	11.5	80
226	Mouse model for pre-clinical study of human cancer immunotherapy. <i>Current Protocols in Immunology</i> , <b>2015</b> , 108, 20.1.1-20.1.43	4	15
225	Microbiota modulation of myeloid cells in cancer therapy. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 103-9	12.5	28
224	Super-enhancers delineate disease-associated regulatory nodes in T cells. <i>Nature</i> , <b>2015</b> , 520, 558-62	50.4	247
223	Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. <i>Cancer Research</i> , <b>2015</b> , 75, 296-305	10.1	212
222	Reprogramming antitumor immunity. <i>Trends in Immunology</i> , <b>2014</b> , 35, 178-85	14.4	29
221	Human memory T cells: generation, compartmentalization and homeostasis. <i>Nature Reviews Immunology</i> , <b>2014</b> , 14, 24-35	36.5	513
220	Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. <i>Immunological Reviews</i> , <b>2014</b> , 257, 264-276	11.3	87
219	Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. <i>European Journal of Immunology</i> , <b>2014</b> , 44, 69-79	6.1	83
218	A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. <i>Human Gene Therapy</i> , <b>2014</b> , 25, 1003-12	4.8	113
217	Engineering the immune response to "self" for effective cancer immunotherapy <b>2014</b> , 2, P22		78
216	Big bang theory of stem-like T cells confirmed. <i>Blood</i> , <b>2014</b> , 124, 476-7	2.2	14
215	Identification of the genomic insertion site of Pmel-1 TCR $\alpha$ and $\beta$ transgenes by next-generation sequencing. <i>PLoS ONE</i> , <b>2014</b> , 9, e96650	3.7	17
214	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , <b>2014</b> , 5, 12472-508	3.3	301
213	HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, LBA3008-LBA3008	2.2	6
212	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors <b>2013</b> , 1, 11		49

211	Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting <b>2013</b> , 1,		4
210	Double or nothing on cancer immunotherapy. <i>Nature Biotechnology</i> , <b>2013</b> , 31, 33-4	44.5	18
209	Lineage relationship of effector and memory T cells. <i>Current Opinion in Immunology</i> , <b>2013</b> , 25, 556-63	7.8	139
208	A "big data" view of the tumor "immunome". <i>Immunity</i> , <b>2013</b> , 39, 631-2	32.3	15
207	Reassessing target antigens for adoptive T-cell therapy. <i>Nature Biotechnology</i> , <b>2013</b> , 31, 999-1008	44.5	143
206	Essentials of Th17 cell commitment and plasticity. <i>Blood</i> , <b>2013</b> , 121, 2402-14	2.2	262
205	Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 727-36	7.4	71
204	Memoirs of a reincarnated T cell. <i>Cell Stem Cell</i> , <b>2013</b> , 12, 6-8	18	11
203	Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2152-9	2.2	163
202	Collapse of the tumor stroma is triggered by IL-12 induction of Fas. <i>Molecular Therapy</i> , <b>2013</b> , 21, 1369-77	11.7	54
201	MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. <i>Immunity</i> , <b>2013</b> , 38, 742-53	32.3	204
200	BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. <i>Nature</i> , <b>2013</b> , 498, 506-10	50.4	264
199	Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. <i>Nature Protocols</i> , <b>2013</b> , 8, 33-42	18.8	138
198	Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. <i>Cancer Research</i> , <b>2013</b> , 73, 3371-80	10.1	75
197	Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. <i>Journal of Immunotherapy</i> , <b>2013</b> , 36, 133-51	5	758
196	T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 6973-8	11.5	143
195	Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 1961-76	16.6	93
194	Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 1125-35	16.6	223

193	Moving T memory stem cells to the clinic. <i>Blood</i> , <b>2013</b> , 121, 567-8	2.2	48
192	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 4479-88	15.9	535
191	Superior T memory stem cell persistence supports long-lived T cell memory. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 594-9	15.9	216
190	The power and pitfalls of IL-12. <i>Blood</i> , <b>2012</b> , 119, 4096-7	2.2	10
189	The stoichiometric production of IL-2 and IFN- $\gamma$ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 149ra120	17.5	47
188	Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. <i>Journal of Immunology</i> , <b>2012</b> , 189, 767-76	5.3	23
187	Paths to stemness: building the ultimate antitumour T cell. <i>Nature Reviews Cancer</i> , <b>2012</b> , 12, 671-84	31.3	376
186	Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1672-83	12.9	199
185	Cellular constituents of immune escape within the tumor microenvironment. <i>Cancer Research</i> , <b>2012</b> , 72, 3125-30	10.1	248
184	Adoptive immunotherapy for cancer: harnessing the T cell response. <i>Nature Reviews Immunology</i> , <b>2012</b> , 12, 269-81	36.5	1192
183	141 The Role of T Memory Stem Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 59, 59	3.1	1
182	Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. <i>Journal of Immunotherapy</i> , <b>2012</b> , 35, 651-60	5	195
181	A human memory T cell subset with stem cell-like properties. <i>Nature Medicine</i> , <b>2011</b> , 17, 1290-7	50.5	1153
180	Th17 cells are long lived and retain a stem cell-like molecular signature. <i>Immunity</i> , <b>2011</b> , 35, 972-85	32.3	316
179	Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. <i>Journal of Immunotherapy</i> , <b>2011</b> , 34, 343-52	5	65
178	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. <i>Blood</i> , <b>2011</b> , 117, 808-14	2.2	226
177	Therapeutic cancer vaccines: are we there yet?. <i>Immunological Reviews</i> , <b>2011</b> , 239, 27-44	11.3	218
176	Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. <i>BMC Cancer</i> , <b>2011</b> , 11, 451	4.8	17



175	Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4550-7	12.9	1434
174	In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 739-49	7.4	40
173	Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 671-83	7.4	55
172	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. <i>Nature Immunology</i> , <b>2011</b> , 12, 1230-7	19.1	136
171	Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. <i>Genome Research</i> , <b>2011</b> , 21, 1650-8	9.7	138
170	Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. <i>Molecular Therapy</i> , <b>2011</b> , 19, 751-9	11.7	174
169	Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5343-52	12.9	204
168	Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 917-24	2.2	1185
167	A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. <i>Journal of Immunology</i> , <b>2011</b> , 186, 685-96	5.3	129
166	Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 37077-84	5.4	6
165	T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. <i>Molecular Therapy</i> , <b>2011</b> , 19, 620-6	11.7	693
164	IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 4746-57	15.9	238
163	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. <i>Nature Medicine</i> , <b>2010</b> , 16, 339-45	50.5	102
162	Reply to: Eatenin does not regulate memory T cell phenotype. <i>Nature Medicine</i> , <b>2010</b> , 16, 514-515	50.5	15
161	T(H)17 cells in tumour immunity and immunotherapy. <i>Nature Reviews Immunology</i> , <b>2010</b> , 10, 248-56	36.5	460
160	Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. <i>Journal of Immunology</i> , <b>2010</b> , 184, 5988-98	5.3	65
159	Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 6171-80	10.1	473
158	Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 651-67	16.6	301

157	Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 637-50	16.6	559
156	Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4695-701	12.9	123
155	CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 6122-31	12.9	231
154	GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. <i>Journal of Immunology</i> , <b>2010</b> , 185, 2828-35	5.3	38
153	Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. <i>Cancer Research</i> , <b>2010</b> , 70, 6725-34	10.1	187
152	Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 1-7	5	197
151	Different adjuvanticity of incomplete Freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 626-9	5	22
150	Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. <i>Blood</i> , <b>2010</b> , 116, 3875-86	2.2	239
149	Can antitumor immunity help to explain "oncogene addiction"? <i>Cancer Cell</i> , <b>2010</b> , 18, 403-5	24.3	15
148	IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells. <i>European Journal of Immunology</i> , <b>2010</b> , 40, 733-43	6.1	14
147	Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 4273-88	15.9	18
146	Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 3953-68	15.9	163
145	Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 17469-74	11.5	302
144	Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000457	7.6	31
143	Pharmacologic induction of CD8+ T cell memory: better living through chemistry. <i>Science Translational Medicine</i> , <b>2009</b> , 1, 11ps12	17.5	52
142	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. <i>Nature Medicine</i> , <b>2009</b> , 15, 808-13	50.5	675
141	Adoptive immunotherapy of cancer using CD4(+) T cells. <i>Current Opinion in Immunology</i> , <b>2009</b> , 21, 200-8	7.8	183
140	T helper 17 cells promote cytotoxic T cell activation in tumor immunity. <i>Immunity</i> , <b>2009</b> , 31, 787-98	32.3	567

139	Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. <i>Ophthalmology</i> , <b>2009</b> , 116, 981-989.e1	7.3	70
138	Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. <i>Trends in Immunology</i> , <b>2009</b> , 30, 592-602	14.4	187
137	High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 677-88	5	17
136	Type 17 CD8+ T cells display enhanced antitumor immunity. <i>Blood</i> , <b>2009</b> , 114, 596-9	2.2	174
135	Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. <i>Blood</i> , <b>2009</b> , 114, 1776-83	2.2	26
134	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. <i>Blood</i> , <b>2009</b> , 114, 535-46	2.2	1077
133	Does IL-17 promote tumor growth?. <i>Blood</i> , <b>2009</b> , 114, 231-2	2.2	24
132	Adoptive cell transfer: a clinical path to effective cancer immunotherapy. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 299-308	31.3	1179
131	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. <i>Blood</i> , <b>2008</b> , 112, 4746-54	2.2	32
130	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. <i>Blood</i> , <b>2008</b> , 111, 5326-33	2.2	320
129	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 8061-6	11.5	105
128	Cancer immunotherapy. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1072	59.2	41
127	TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation. <i>PLoS Biology</i> , <b>2008</b> , 6, e191	9.7	15
126	Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5610-8	12.9	179
125	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5233-9	2.2	1045
124	Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. <i>Blood</i> , <b>2008</b> , 111, 4588-95	2.2	13
123	Tumor-specific Th17-polarized cells eradicate large established melanoma. <i>Blood</i> , <b>2008</b> , 112, 362-73	2.2	615
122	T-cell receptor gene therapy of established tumors in a murine melanoma model. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 1-6	5	54

121	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 2197-204	15.9	365
120	Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. <i>Cancer Research</i> , <b>2007</b> , 67, 2425-9	10.1	78
119	5-AZA-2'-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. <i>Cancer Research</i> , <b>2007</b> , 67, 2901-2901	10.1	
118	Toll-like receptors in tumor immunotherapy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5280-9	12.9	101
117	Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. <i>Journal of Molecular Biology</i> , <b>2007</b> , 372, 1123-36	6.5	77
116	Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 492-501	15.9	155
115	Programming CD8+ T cells for effective immunotherapy. <i>Current Opinion in Immunology</i> , <b>2006</b> , 18, 363-70	7.8	59
114	Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 2592-9	6.1	44
113	De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. <i>Cancer Research</i> , <b>2006</b> , 66, 1105-13	10.1	123
112	The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. <i>Cancer Research</i> , <b>2006</b> , 66, 1132-8	10.1	42
111	Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2526-37	12.9	47
110	Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. <i>Journal of Immunology</i> , <b>2006</b> , 176, 5213-22	5.3	72
109	Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. <i>Cancer Research</i> , <b>2006</b> , 66, 4904-12	10.1	179
108	High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. <i>Molecular Therapy</i> , <b>2006</b> , 13, 151-9	11.7	229
107	Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 668-81		258
106	Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. <i>Journal of Immunology</i> , <b>2006</b> , 176, 5255-66	5.3	96
105	Cancer regression in patients after transfer of genetically engineered lymphocytes. <i>Science</i> , <b>2006</b> , 314, 126-9	33.3	2001
104	Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. <i>Vaccine</i> , <b>2006</b> , 24, 5110-8	4.1	41

103	CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. <i>Blood</i> , <b>2006</b> , 108, 3818-23	2.2	51
102	Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. <i>Journal of Immunotherapy</i> , <b>2006</b> , 29, 224-31	5	28
101	CD8+ T-cell memory in tumor immunology and immunotherapy. <i>Immunological Reviews</i> , <b>2006</b> , 211, 214-243	24.3	369
100	Cross-priming utilizes antigen not available to the direct presentation pathway. <i>Immunology</i> , <b>2006</b> , 119, 63-73	7.8	27
99	Adoptive immunotherapy for cancer: building on success. <i>Nature Reviews Immunology</i> , <b>2006</b> , 6, 383-93	36.5	724
98	Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. <i>Blood</i> , <b>2006</b> , 108, 5210-5210	2.2	
97	Treatment of Established B16 Murine Melanoma Tumors with Tyrp-1 Specific CD4+ Lymphocytes.. <i>Blood</i> , <b>2006</b> , 108, 3688-3688	2.2	
96	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2346-57	2.2	1294
95	Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. <i>Cancer Research</i> , <b>2005</b> , 65, 10569-77	10.1	77
94	Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. <i>Trends in Immunology</i> , <b>2005</b> , 26, 111-7	14.4	346
93	Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 517-24	5	48
92	CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 120-8	5	165
91	Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. <i>Current Opinion in Immunology</i> , <b>2005</b> , 17, 195-201	7.8	88
90	Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6043-53	2.2	880
89	Bcl-2 overexpression enhances tumor-specific T-cell survival. <i>Cancer Research</i> , <b>2005</b> , 65, 2001-8	10.1	109
88	Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 201, 139-48	16.6	576
87	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 1616-26	15.9	701
86	Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 202, 907-12	16.6	809

85	Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. <i>Journal of Immunology</i> , <b>2005</b> , 174, 1462-71	5.3	86
84	Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. <i>Journal of Immunology</i> , <b>2005</b> , 174, 4812-20	5.3	89
83	Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. <i>Journal of Immunology</i> , <b>2005</b> , 175, 6169-76	5.3	391
82	CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. <i>Journal of Immunology</i> , <b>2005</b> , 174, 2591-601	5.3	595
81	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 9571-6	11.5	692
80	Use of standard criteria for assessment of cancer vaccines. <i>Lancet Oncology</i> , <b>2005</b> , 6, 3-4	21.7	9
79	Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. <i>Cancer Research</i> , <b>2004</b> , 64, 6783-90	10.1	105
78	IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 1969-74	11.5	441
77	Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. <i>Journal of Immunology</i> , <b>2004</b> , 173, 7209-16	5.3	100
76	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. <i>Journal of Leukocyte Biology</i> , <b>2004</b> , 76, 333-7	6.5	42
75	Cancer immunotherapy: moving beyond current vaccines. <i>Nature Medicine</i> , <b>2004</b> , 10, 909-15	50.5	2369
74	Reply to "Cancer vaccines: pessimism in check". <i>Nature Medicine</i> , <b>2004</b> , 10, 1279-1280	50.5	15
73	Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. <i>Vaccine</i> , <b>2004</b> , 22, 1537-44	4.1	61
72	Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 551-559	15.9	93
71	Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 551-9	15.9	51
70	Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. <i>Human Gene Therapy</i> , <b>2003</b> , 14, 709-14	4.8	99
69	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 8372-7	11.5	1325
68	Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 198, 569-80	16.6	754

67	High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. <i>Journal of Immunology</i> , <b>2003</b> , 171, 3287-95	5.3	198
66	Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. <i>Journal of Immunotherapy</i> , <b>2003</b> , 26, 349-56	5	109
65	Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. <i>Journal of Immunotherapy</i> , <b>2003</b> , 26, 385-93	5	53
64	Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. <i>Nature Medicine</i> , <b>2003</b> , 9, 33-9	50.5	240
63	Immune evasion by murine melanoma mediated through CC chemokine receptor-10. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 198, 1337-47	16.6	133
62	Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. <i>Journal of Immunology</i> , <b>2003</b> , 170, 1579-85	5.3	21
61	DNA vaccines and apoptosis: to kill or not to kill?. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 112, 22-24	15.9	20
60	DNA vaccines and apoptosis: to kill or not to kill?. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 112, 22-4	15.9	8
59	Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2973-80	12.9	68
58	Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. <i>Prostate</i> , <b>2002</b> , 53, 183-91	4.2	8
57	MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. <i>Cancer Gene Therapy</i> , <b>2002</b> , 9, 946-50	5.4	24
56	Natural selection of tumor variants in the generation of "tumor escape" phenotypes. <i>Nature Immunology</i> , <b>2002</b> , 3, 999-1005	19.1	799
55	Assumptions of the tumor 'escape' hypothesis. <i>Seminars in Cancer Biology</i> , <b>2002</b> , 12, 81-6	12.7	25
54	Intensity of the vaccine-elicited immune response determines tumor clearance. <i>Journal of Immunology</i> , <b>2002</b> , 168, 338-47	5.3	77
53	Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. <i>Science</i> , <b>2002</b> , 298, 850-4	33.3	2293
52	Cancer vaccines: progress reveals new complexities. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 289-294	15.9	62
51	Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 109, 1463-70	15.9	24
50	Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 109, 1463-1470	15.9	63

49	Cancer vaccines: progress reveals new complexities. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 289-94	15.9	25
48	Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. <i>Cancer Research</i> , <b>2002</b> , 62, 5144-7	10.1	20
47	Countering the 'counterattack' hypothesis. <i>Nature Medicine</i> , <b>2001</b> , 7, 259	50.5	54
46	B16 as a mouse model for human melanoma. <i>Current Protocols in Immunology</i> , <b>2001</b> , Chapter 20, Unit 20.1	4	224
45	Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. <i>Journal of Experimental Medicine</i> , <b>2001</b> , 194, 481-9	16.6	274
44	Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. <i>Journal of Immunotherapy</i> , <b>2001</b> , 24, 193-194	5	6
43	Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. <i>Current Opinion in Immunology</i> , <b>2000</b> , 12, 597-603	7.8	128
42	Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. <i>Nature Medicine</i> , <b>2000</b> , 6, 493-5	50.5	222
41	Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. <i>World Journal of Urology</i> , <b>2000</b> , 18, 136-42	4	7
40	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. <i>Blood</i> , <b>2000</b> , 96, 3838-3846	2.2	442
39	Poxviruses as vectors for cancer immunotherapy <b>2000</b> , 47-61		5
38	Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 191, 1221-32	16.6	145
37	Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. <i>Journal of Immunology</i> , <b>2000</b> , 164, 3535-42	5.3	111
36	Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. <i>Journal of Interferon and Cytokine Research</i> , <b>2000</b> , 20, 589-96	3.5	9
35	Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. <i>Journal of Immunology</i> , <b>2000</b> , 164, 562-5	5.3	146
34	Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. <i>Journal of Immunology</i> , <b>2000</b> , 165, 1153-9	5.3	118
33	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. <i>Blood</i> , <b>2000</b> , 96, 3838-3846	2.2	54
32	Autoimmunity and the Immunotherapy of Cancer: Targeting the "Self" to Destroy the "Other". <i>Critical Reviews in Immunology</i> , <b>2000</b> , 20, 18	1.8	47



31	Cancer therapy using a self-replicating RNA vaccine. <i>Nature Medicine</i> , <b>1999</b> , 5, 823-7	50.5	275
30	Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. <i>International Journal of Cancer</i> , <b>1999</b> , 80, 781-90	7.5	60
29	DNA and RNA-based vaccines: principles, progress and prospects. <i>Vaccine</i> , <b>1999</b> , 18, 765-77	4.1	248
28	Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. <i>Journal of Immunotherapy</i> , <b>1999</b> , 22, 489-96	5	35
27	Developing recombinant and synthetic vaccines for the treatment of melanoma. <i>Current Opinion in Oncology</i> , <b>1999</b> , 11, 50-7	4.2	46
26	Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model <b>1999</b> , 80, 781		1
25	Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. <i>Virology</i> , <b>1998</b> , 249, 89-97	3.6	23
24	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. <i>Nature Medicine</i> , <b>1998</b> , 4, 321-7	50.5	1539
23	Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. <i>Journal of Immunological Methods</i> , <b>1998</b> , 214, 51-62	2.5	11
22	Cancer vaccines '98: a reductionistic approach. Bethesda, MD, USA, 27-28 April 1998. <i>Trends in Molecular Medicine</i> , <b>1998</b> , 4, 327		5
21	T cell-tumor cell: a fatal interaction?. <i>Cancer Immunology, Immunotherapy</i> , <b>1998</b> , 47, 65-71	7.4	54
20	Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 188, 1075-82	16.6	495
19	gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 188, 277-86	16.6	391
18	Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. <i>Journal of the National Cancer Institute</i> , <b>1997</b> , 89, 1595-601	9.7	133
17	Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. <i>Journal of Immunotherapy</i> , <b>1997</b> , 20, 15-25	5	92
16	Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. <i>Journal of Immunotherapy</i> , <b>1997</b> , 20, 276-86	5	77
15	Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. <i>Methods</i> , <b>1997</b> , 12, 117-23	4.6	48
14	Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. <i>Vaccine</i> , <b>1997</b> , 15, 387-94	4.1	79

13	The next wave of recombinant and synthetic anticancer vaccines. <i>Seminars in Cancer Biology</i> , <b>1995</b> , 6, 337-47	12.7	13
12	Molecular characterization of defective antigen processing in human prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>1995</b> , 87, 280-5	9.7	182
11	Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. <i>Journal of Immunotherapy</i> , <b>1995</b> , 18, 139-46	5	23
10	HLA associations in the antitumor response against malignant melanoma. <i>Journal of Immunotherapy</i> , <b>1995</b> , 18, 242-52	5	53
9	Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. <i>Cancer Immunology, Immunotherapy</i> , <b>1994</b> , 39, 73-83	7.4	19
8	Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. <i>Journal of Immunotherapy</i> , <b>1994</b> , 16, 13-23	5	39
7	The multiple uses of viruses for studying antigen processing. <i>Seminars in Virology</i> , <b>1993</b> , 4, 109-116		6
6	Molecular mechanisms used by tumors to escape immune recognition: immunogenethrapy and the cell biology of major histocompatibility complex class I. <i>Journal of Immunotherapy</i> , <b>1993</b> , 14, 182-90	5	97
5	Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. <i>Cancer Immunology, Immunotherapy</i> , <b>1993</b> , 37, 286-92	7.4	23
4	The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. <i>Metabolism: Clinical and Experimental</i> , <b>1991</b> , 40, 59-65	12.7	59
3	Internal Checkpoint Regulates T Cell Neoantigen Reactivity and Susceptibility to PD1 Blockade. <i>SSRN Electronic Journal</i> ,	1	1
2	Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas		1
1	Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade		4